BRNS
Barinthus Biotherapeutics plc
Price Chart
Latest Quote
$0.68
-0.01 (-2.03%)
Current Price
| Previous Close | $0.70 |
| Open | $0.70 |
| Day High | $0.70 |
| Day Low | $0.68 |
| Volume | 2,859 |
Stock Information
| Shares Outstanding | 40.85M |
| Total Debt | $11.01M |
| Cash Equivalents | $65.86M |
| Net Income | $-52.31M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $27.05M |
| EPS (TTM) | $-1.29 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-26.21M |
| Income | $-52.31M |
| Book/sh | $1.62 |
| Cash/sh | $1.61 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 5.60 |
| Current Ratio | 6.05 |
| Debt/Eq | 16.56 |
Returns & Margins
| ROA | -23.21% |
| ROE | -57.49% |
Ownership
| Insider Ownership | 19.81% |
| Institutional Ownership | 44.30% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.58 |
| P/B | 0.41 |
Analyst Data
| Recommendation | none |
| Target Price | $5.50 |
Technical Indicators
| SMA20 | $0.69 |
| SMA50 | $0.66 |
| SMA200 | $0.82 |
| RSI | 47.40 |
| ATR | 0.0516 |
| Shares Float | 27.26M |
| Short Float | 0.01% |
| Short Ratio | 0.16 |
| Volatility | -0.40 |
| Rel Volume | 0.06 |
Performance History
| Week | -8.55% |
| Month | -3.20% |
| Quarter | +5.10% |
| 6 Months | -10.41% |
| YTD | -9.92% |
| Year | -24.76% |
| 3 Years | -72.98% |
| 5 Years | -95.71% |
| 10 Years | -95.30% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.66 | 9,748 |
| 2026-06-17 | $0.70 | 9,900 |
| 2026-06-16 | $0.70 | 72,800 |
| 2026-06-15 | $0.70 | 182,000 |
| 2026-06-12 | $0.67 | 85,600 |
| 2026-06-11 | $0.72 | 17,700 |
| 2026-06-10 | $0.69 | 23,800 |
| 2026-06-09 | $0.72 | 103,900 |
| 2026-06-08 | $0.72 | 1,792,200 |
| 2026-06-05 | $0.65 | 687,000 |
| 2026-06-04 | $0.70 | 0 |
| 2026-06-03 | $0.70 | 4,000 |
| 2026-06-02 | $0.66 | 3,200 |
| 2026-06-01 | $0.68 | 1,200 |
| 2026-05-29 | $0.68 | 2,300 |
| 2026-05-28 | $0.68 | 3,500 |
| 2026-05-27 | $0.70 | 4,300 |
| 2026-05-26 | $0.68 | 21,000 |
| 2026-05-22 | $0.69 | 8,000 |
| 2026-05-21 | $0.70 | 11,900 |
| 2026-05-20 | $0.69 | 50,900 |
| 2026-05-19 | $0.68 | 19,500 |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $14,969,000 | $802,000 | $44,703,000 |
| Operating Revenue | $0 | $14,969,000 | $802,000 | $44,703,000 |
| Expenses | ||||
| Interest Expense | $51,000 | $53,000 | $28,000 | $19,000 |
| Total Expenses | $63,888,000 | $66,747,000 | $81,255,000 | $47,504,000 |
| Other Income Expense | $-4,651,000 | $-12,074,000 | $1,082,000 | $567,000 |
| Other Non Operating Income Expenses | $16,000 | $135,000 | $1,082,000 | $567,000 |
| Net Non Operating Interest Income Expense | $1,906,000 | $2,625,000 | $2,849,000 | $3,084,000 |
| Interest Expense Non Operating | $51,000 | $53,000 | $28,000 | $19,000 |
| Operating Expense | $63,888,000 | $66,747,000 | $81,255,000 | $47,504,000 |
| Other Operating Expenses | $-506,000 | $-1,176,000 | - | - |
| General And Administrative Expense | $40,830,000 | $29,670,000 | $39,842,000 | $6,394,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-66,428,000 | $-61,074,000 | $-73,347,000 | $5,342,000 |
| Net Interest Income | $1,906,000 | $2,625,000 | $2,849,000 | $3,084,000 |
| Interest Income | $1,957,000 | $2,678,000 | $2,877,000 | $3,103,000 |
| Normalized Income | $-61,774,068 | $-48,873,546 | $-73,347,000 | $5,342,000 |
| Net Income From Continuing And Discontinued Operation | $-66,428,000 | $-61,074,000 | $-73,347,000 | $5,342,000 |
| Total Operating Income As Reported | $-70,555,000 | $-67,970,000 | $-83,914,000 | $-4,041,000 |
| Net Income Common Stockholders | $-66,428,000 | $-61,074,000 | $-73,347,000 | $5,342,000 |
| Net Income | $-66,428,000 | $-61,074,000 | $-73,347,000 | $5,342,000 |
| Net Income Including Noncontrolling Interests | $-66,458,000 | $-61,183,000 | $-73,447,000 | $5,321,000 |
| Net Income Continuous Operations | $-66,458,000 | $-61,183,000 | $-73,447,000 | $5,321,000 |
| Pretax Income | $-66,633,000 | $-61,227,000 | $-76,522,000 | $850,000 |
| Special Income Charges | $-4,667,000 | $-12,209,000 | $0 | $0 |
| Interest Income Non Operating | $1,957,000 | $2,678,000 | $2,877,000 | $3,103,000 |
| Operating Income | $-63,888,000 | $-51,778,000 | $-80,453,000 | $-2,801,000 |
| Per Share | ||||
| Diluted EPS | $-1.64 | $-1.55 | $-1.91 | $0.14 |
| Basic EPS | $-1.64 | $-1.55 | $-1.91 | $0.14 |
| Other | ||||
| Tax Effect Of Unusual Items | $-13,068 | $-8,546 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-56,070,000 | $-43,165,000 | $-71,065,000 | $5,192,000 |
| Total Unusual Items | $-4,667,000 | $-12,209,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-4,667,000 | $-12,209,000 | $0 | $0 |
| Reconciled Depreciation | $5,845,000 | $5,800,000 | $5,429,000 | $4,323,000 |
| EBITDA (Bullshit earnings) | $-60,737,000 | $-55,374,000 | $-71,065,000 | $5,192,000 |
| EBIT | $-66,582,000 | $-61,174,000 | $-76,494,000 | $869,000 |
| Diluted Average Shares | $40,527,218 | $39,348,240 | $38,386,491 | $38,169,307 |
| Basic Average Shares | $40,527,218 | $39,348,240 | $38,386,491 | $37,248,126 |
| Diluted NI Availto Com Stockholders | $-66,428,000 | $-61,074,000 | $-73,347,000 | $5,342,000 |
| Minority Interests | $30,000 | $109,000 | $100,000 | $21,000 |
| Tax Provision | $-175,000 | $-44,000 | $-3,075,000 | $-4,471,000 |
| Impairment Of Capital Assets | $4,667,000 | $12,209,000 | $0 | - |
| Research And Development | $23,564,000 | $38,253,000 | $41,413,000 | $41,110,000 |
| Selling General And Administration | $40,830,000 | $29,670,000 | $39,842,000 | $6,394,000 |
| Other Gand A | $40,830,000 | $29,670,000 | $39,842,000 | $6,394,000 |
| Other Special Charges | - | - | - | - |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $59,920,000 | $108,082,000 | $149,467,000 | $202,418,000 |
| Total Assets | $98,169,000 | $160,327,000 | $214,506,000 | $270,205,000 |
| Total Non Current Assets | $20,379,000 | $34,585,000 | $57,601,000 | $57,164,000 |
| Other Non Current Assets | $930,000 | $881,000 | $882,000 | $976,000 |
| Goodwill And Other Intangible Assets | $14,288,000 | $21,947,000 | $37,317,000 | $40,478,000 |
| Current Assets | $77,790,000 | $125,742,000 | $156,905,000 | $213,041,000 |
| Other Current Assets | $115,000 | $344,000 | $1,474,000 | $611,000 |
| Restricted Cash | $1,396,000 | $1,738,000 | $0 | - |
| Prepaid Assets | $4,518,000 | $5,859,000 | - | $5,887,000 |
| Receivables | $1,305,000 | $7,139,000 | $13,341,000 | $18,045,000 |
| Other Receivables | $1,108,000 | $7,139,000 | $10,310,000 | $12,198,000 |
| Taxes Receivable | $197,000 | $0 | $3,031,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $70,456,000 | $110,662,000 | $142,090,000 | $194,385,000 |
| Cash And Cash Equivalents | $70,456,000 | $110,662,000 | $142,090,000 | $194,385,000 |
| Other Intangible Assets | - | $21,947,000 | $25,108,000 | $28,269,000 |
| Accounts Receivable | - | - | $0 | $5,847,000 |
| Debt | ||||
| Total Debt | $11,281,000 | $12,007,000 | $12,976,000 | $8,773,000 |
| Long Term Debt And Capital Lease Obligation | $9,258,000 | $10,087,000 | $11,191,000 | $8,340,000 |
| Current Debt And Capital Lease Obligation | $2,023,000 | $1,920,000 | $1,785,000 | $433,000 |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $23,877,000 | $30,192,000 | $27,511,000 | $27,004,000 |
| Total Non Current Liabilities Net Minority Interest | $13,859,000 | $14,535,000 | $14,913,000 | $14,762,000 |
| Other Non Current Liabilities | $4,347,000 | $4,010,000 | $3,148,000 | $2,676,000 |
| Non Current Deferred Liabilities | $254,000 | $438,000 | $574,000 | $3,746,000 |
| Non Current Deferred Taxes Liabilities | $254,000 | $438,000 | $574,000 | $3,746,000 |
| Current Liabilities | $10,018,000 | $15,657,000 | $12,598,000 | $12,242,000 |
| Current Deferred Liabilities | $1,396,000 | $1,738,000 | $0 | $0 |
| Payables And Accrued Expenses | $6,599,000 | $10,225,000 | $8,401,000 | $9,884,000 |
| Payables | $350,000 | $4,890,000 | $1,601,000 | $3,748,000 |
| Total Tax Payable | $0 | $2,416,000 | $0 | - |
| Accounts Payable | $350,000 | $2,474,000 | $1,601,000 | $3,748,000 |
| Equity | ||||
| Common Stock Equity | $74,208,000 | $130,029,000 | $186,784,000 | $242,896,000 |
| Total Equity Gross Minority Interest | $74,292,000 | $130,135,000 | $186,995,000 | $243,201,000 |
| Stockholders Equity | $74,208,000 | $130,029,000 | $186,784,000 | $242,896,000 |
| Other Equity Interest | $86,000 | $86,000 | $86,000 | $94,000 |
| Gains Losses Not Affecting Retained Earnings | $-15,731,000 | $-25,868,000 | $-23,315,000 | $-33,460,000 |
| Retained Earnings | $-304,092,000 | $-237,664,000 | $-176,590,000 | $-103,243,000 |
| Other | ||||
| Ordinary Shares Number | $40,848,893 | $40,234,663 | $38,643,540 | $37,683,531 |
| Share Issued | $40,848,893 | $40,234,663 | $38,643,540 | $37,683,531 |
| Tangible Book Value | $59,920,000 | $108,082,000 | $149,467,000 | $202,418,000 |
| Invested Capital | $74,208,000 | $130,029,000 | $186,784,000 | $242,896,000 |
| Working Capital | $67,772,000 | $110,085,000 | $144,307,000 | $200,799,000 |
| Capital Lease Obligations | $11,281,000 | $12,007,000 | $12,976,000 | $8,773,000 |
| Total Capitalization | $74,208,000 | $130,029,000 | $186,784,000 | $242,896,000 |
| Minority Interest | $84,000 | $106,000 | $211,000 | $305,000 |
| Foreign Currency Translation Adjustments | $-15,731,000 | $-25,868,000 | $-23,315,000 | $-33,460,000 |
| Additional Paid In Capital | $393,944,000 | $393,474,000 | $386,602,000 | $379,504,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $9,258,000 | $10,087,000 | $11,191,000 | $8,340,000 |
| Current Deferred Revenue | $1,396,000 | $1,738,000 | $0 | $0 |
| Current Capital Lease Obligation | $2,023,000 | $1,920,000 | $1,785,000 | $433,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $0 | $1,774,000 | $2,412,000 | $1,925,000 |
| Current Accrued Expenses | $6,249,000 | $5,335,000 | $6,800,000 | $6,136,000 |
| Net PPE | $5,161,000 | $11,757,000 | $19,402,000 | $15,710,000 |
| Accumulated Depreciation | $-7,591,000 | $-9,420,000 | $-3,688,000 | $-1,322,000 |
| Gross PPE | $12,752,000 | $21,177,000 | $23,090,000 | $17,032,000 |
| Leases | $8,910,000 | $9,282,000 | $8,673,000 | $3,926,000 |
| Other Properties | $3,390,000 | $10,562,000 | $13,309,000 | $12,065,000 |
| Machinery Furniture Equipment | $452,000 | $1,333,000 | $1,108,000 | $1,041,000 |
| Properties | $0 | $0 | $0 | $0 |
| Goodwill | - | $0 | $12,209,000 | $12,209,000 |
| Duefrom Related Parties Current | - | - | - | $5,524,000 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-48,016,000 | $-29,832,000 | $-56,338,000 | $-20,569,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-47,979,000 | $-28,940,000 | $-50,925,000 | $-14,431,000 |
| Cash Flow From Continuing Operating Activities | $-47,979,000 | $-28,940,000 | $-50,925,000 | $-14,431,000 |
| Operating Gains Losses | $3,497,000 | $-649,000 | $7,531,000 | $-25,253,000 |
| Investing Activities | ||||
| Capital Expenditure | $-37,000 | $-892,000 | $-5,413,000 | $-6,138,000 |
| Investing Cash Flow | $416,000 | $-892,000 | $-5,413,000 | $-5,750,000 |
| Cash Flow From Continuing Investing Activities | $416,000 | $-892,000 | $-5,413,000 | $-5,750,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $2,163,000 | $2,035,000 | $484,000 |
| Financing Cash Flow | $2,000 | $2,163,000 | $1,872,000 | $325,000 |
| Cash Flow From Continuing Financing Activities | $2,000 | $2,163,000 | $1,872,000 | $325,000 |
| Net Common Stock Issuance | $0 | $2,163,000 | $2,035,000 | $484,000 |
| Common Stock Issuance | $0 | $2,163,000 | $2,035,000 | $484,000 |
| Net Other Financing Charges | - | - | $-163,000 | - |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $71,852,000 | $112,400,000 | $142,090,000 | $194,385,000 |
| Beginning Cash Position | $112,400,000 | $142,090,000 | $194,385,000 | $214,054,000 |
| Effect Of Exchange Rate Changes | $7,013,000 | $-2,021,000 | $2,171,000 | $187,000 |
| Changes In Cash | $-47,561,000 | $-27,669,000 | $-54,466,000 | $-19,856,000 |
| Proceeds From Stock Option Exercised | $2,000 | $0 | $0 | $0 |
| Net PPE Purchase And Sale | $416,000 | $-892,000 | $-5,413,000 | $-5,750,000 |
| Sale Of PPE | $453,000 | $0 | $0 | $388,000 |
| Purchase Of PPE | $-37,000 | $-892,000 | $-5,413,000 | $-6,138,000 |
| Change In Working Capital | $-359,000 | $2,601,000 | $6,171,000 | $-5,524,000 |
| Change In Other Working Capital | $-506,000 | $1,738,000 | - | $-183,000 |
| Change In Other Current Liabilities | $-1,979,000 | $-1,789,000 | $-445,000 | $0 |
| Change In Payables And Accrued Expense | $-5,995,000 | $1,354,000 | $-1,385,000 | $1,891,000 |
| Change In Accrued Expense | $-3,793,000 | $456,000 | $1,993,000 | $751,000 |
| Change In Payable | $-2,202,000 | $898,000 | $-3,378,000 | $1,140,000 |
| Change In Account Payable | $-2,202,000 | $898,000 | $-3,378,000 | $1,140,000 |
| Change In Prepaid Assets | $1,704,000 | $3,643,000 | $2,200,000 | $-2,170,000 |
| Change In Receivables | $6,417,000 | $-2,345,000 | $5,673,000 | $-4,675,000 |
| Other Non Cash Items | $3,409,000 | $2,357,000 | $1,411,000 | $1,162,000 |
| Stock Based Compensation | $468,000 | $4,709,000 | $5,055,000 | $9,877,000 |
| Asset Impairment Charge | $5,794,000 | $17,469,000 | $0 | - |
| Deferred Tax | $-175,000 | $-44,000 | $-3,075,000 | $-4,337,000 |
| Deferred Income Tax | $-175,000 | $-44,000 | $-3,075,000 | $-4,337,000 |
| Depreciation Amortization Depletion | $5,845,000 | $5,800,000 | $5,429,000 | $4,323,000 |
| Depreciation And Amortization | $5,845,000 | $5,800,000 | $5,429,000 | $4,323,000 |
| Net Foreign Currency Exchange Gain Loss | $3,742,000 | $-649,000 | $7,531,000 | $-24,905,000 |
| Gain Loss On Sale Of PPE | $-245,000 | $0 | $0 | $-348,000 |
| Net Income From Continuing Operations | $-66,458,000 | $-61,183,000 | $-73,447,000 | $5,321,000 |
| Change In Other Current Assets | - | $0 | $128,000 | $-387,000 |
| Changes In Account Receivables | - | $0 | $5,800,000 | $-5,833,000 |
| Repayment Of Debt | - | - | $0 | $-159,000 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Net Issuance Payments Of Debt | - | - | $0 | $-159,000 |
| Net Long Term Debt Issuance | - | - | $0 | $-159,000 |
| Long Term Debt Payments | - | - | $0 | $-159,000 |
| Net Short Term Debt Issuance | - | - | - | $-159,000 |
| Short Term Debt Payments | - | - | - | $-159,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-18